作者: Charles Kuntz IV , Christopher I Shaffrey , Stephen L Ondra , Atiq A Durrani , Praveen V Mummaneni
DOI: 10.1227/01.NEU.0000313120.81565.D7
关键词:
摘要: OBJECTIVE To evaluate the role of stereotactic radiosurgery (SRS) in management recurrent or residual intracranial hemangioblastomas, we assessed tumor control, survival, and complications 32 consecutive patients. METHODS We retrospectively reviewed records hemangioblastoma patients (74 tumors) who underwent gamma knife SRS. The median patient age was 43.8 years (range, 21.3-79.4 yr). Thirty-one had undergone previous surgical resections. Nineteen sporadic lesions (22 tumors), 13 von Hippel-Lindau disease-associated hemangioblastomas (52 tumors). SRS target volume 0.72 mL 0.08-16.6 mL), marginal dose 16.0 Gy 11-20 Gy). RESULTS At a 50.1 months 6.0-165.4 mo), seven died from disease progression, one secondary to heart failure. overall survival after 100%, 94.4%, 68.7% at 1, 3, 7 years, respectively. Follow-up imaging studies demonstrated control 68 tumors (91.9%). progression-free 5 96.9%, 95.0%, 89.9%, Factors associated with an improved included hemangioblastoma, solid tumor, lower volume, greater dose. CONCLUSION is important tool high rate low risk adverse radiation effects.